The German Cancer Society has certified the Center for Personalized Medicine (ZPM) at Heidelberg University Hospital. At the ZPM Heidelberg, patients with advanced and rare cancers and, in future, people with severe chronic inflammatory diseases will receive a molecular genetic analysis. The detailed information can open up new treatment options for those affected.

The progression of multiple sclerosis (MS) can usually be slowed down with medication, but a cure is currently not possible. It is now established that Epstein-Barr viruses are involved in the development of MS. However, it is not known how the pathogens trigger the disease. The European Union is now funding the international research consortium BEHIND-MS as part of its HORIZON Europe program.

Pancreatic cancer is one of the deadliest types of cancers in humans. Chemotherapies attack not only the tumor cells but also healthy cells throughout the body. Innovative nanoparticles could be a new approach to treat cancer more precisely. The approach was developed by a research team from the Max Planck Institute (MPI) for Multidisciplinary Sciences, the University Medical Center Göttingen (UMG), and the Karlsruhe Institute of Technology.

All cancer cells - even those within the same tumor - differ from each other and change over the course of a cancer disease. Scientists at Heidelberg University Hospital, the Medical Faculty in Heidelberg and the German Cancer Research Center discovered molecular changes in multiple myeloma that help individual cancer cells to survive therapy.

Nanoparticles as drug carriers - 09/11/2023

Inhalation of nanocarriers for antibiotics against resistant tuberculosis pathogens

Around ten million people worldwide still contract tuberculosis every year. With an estimated 1.4 million deaths a year, tuberculosis was the world’s deadliest infectious disease until COVID-19. The high mortality rate is down to the sophisticated biology of the pathogen Mycobacterium tuberculosis. A team of researchers from the KIT and the Research Centre Borstel (FZB) has developed a method that aims to outsmart the bacterium once and for all.

CAR-T cell therapy is a last hope for many patients with blood, bone marrow or lymph gland cancer when other treatments are unsuccessful. A limiting factor of this very effective and safe therapy is that the cells used in the process quickly reach a state of exhaustion. Researchers at the University of Freiburg have now been able to prevent this exhaustion and thus significantly improve the effect of the therapy in a preclinical animal model.

Jun.-Prof. Dr. Priscilla Briquez, junior professor at the Department of General and Visceral Surgery at the Freiburg University Medical Center and member of the Medical Faculty at the University of Freiburg, has received a European Research Council (ERC) Starting Grant from the European Commission. Her DRESSCODE project will receive a total of 1.5 million euros funding for five years.

Epigenetically active drugs enable the cell to read parts of the genome that were previously blocked and inaccessible. This leads to the formation of new mRNA transcripts and also new proteins, as scientists from the German Cancer Research Center and the University Hospital Tübingen have now published. These "therapy-induced epitopes" could help the immune system recognize cancer cells.

Epigenetically active drugs enable the cell to read parts of the genome that were previously blocked and inaccessible. This leads to the formation of new mRNA transcripts and also new proteins, as scientists from the German Cancer Research Center and the University Hospital Tübingen have now published. These "therapy-induced epitopes" could help the immune system recognize cancer cells.

A researcher team from Ecole Polytechnique Federal de Lausanne led by Dr. Vivek Thacker now group leader at the Department of Infectious Diseases at Heidelberg University Hospital have studied why tuberculosis bacteria form long strands and how this affects their infectivity. Their findings could lead to new therapies and have now been published in the journal Cell.

A phase I clinical trial is now starting at Tuebingen University Hospital in the Clinical Collaboration Unit (CCU) Translational Immunology, in collaboration with the Department of Internal Medicine I, which is investigating the therapeutic cancer peptide vaccine Fusion-VAC-XS15 in combination with immune checkpoint blockade by atezolizumab (Tecentriq®).

A research team of scientists from the Fraunhofer IPA, the Bosch Digital Innovation Hub at Bosch Health Campus and the Institute of Image-Guided Surgery (IHU) of Strasbourg has jointly launched the DAIOR project. Within the framework of the project, the project partners are working on realizing the operating room of the future with help of artificial intelligence and robot assisted telemedicine.

Help with osteoarthritis of the knee - 27/09/2023

Individualised knee-joint cartilage: artificial tissue that fits

Knee joints are subject to considerable stress throughout our lives. The natural shock absorber cartilage wears out over a lifetime, so many people develop knee osteoarthritis. Treatment is available in the form of artificial cartilage. This "off-the-shelf" tissue often does not grow well. Researchers are developing an individualised cartilage replacement made from biomaterial that is produced by 3D printing based on MRI images.

Tumor vaccines can help the body fight cancer. These vaccines alert the patient's immune system to proteins that are harbouring cancer-typical alterations. Physicians and cancer researchers from Heidelberg and Mannheim have now treated adult patients with advanced midline gliomas, difficult-to-treat brain tumors, with a peptide vaccine for the first time.

Project SMARTGAIT - 13/09/2023

Safe and cost-effective analysis of neurological gait disorders with AI

Stroke, Parkinson's disease and multiple sclerosis often resulting in gait disorders in those affected. Gait analyses play a crucial role in the successful evaluation and therapy of such disorders. Current measurement methods are costly and time-consuming. The SMARTGAIT project is therefore developing an innovative AI-based system aimed at performing meaningful gait analyses with the help of simple smartphone video recordings.

The computational design of new proteins for biomedical or other applications involves long computing times on powerful servers. A joint team of researchers from the Max Planck Institute for Biology Tübingen and the University Hospital Tübingen has now developed and tested a new computational method to greatly speed up the necessary energy calculations. Their framework allows for a precise and efficient design of functional proteins.

Project BlindZero - 03/08/2023

Hope for patients with eye diseases: human cornea from 3D printers

Thousands of cornea transplants are performed every year. However, donors are rare and the procedure is not always without complications. Researchers at the University of Heidelberg are developing an innovative technique in the project BlindZero. It involves ‘printing’ human corneas directly onto patients’ eyes using 3D bioprinting. The reprogrammed genetically engineered cells used for this purpose are not expected to cause a rejection reaction.

Tumour organoids facilitate drug discovery - 20/07/2023

Drug screening for children with cancer using patient-specific miniature tumours

Standard drugs often don’t work in children and adolescents with recurrent cancer. Researchers from the Hopp Children's Tumour Centre (KITZ) and the German Cancer Research Center (DKFZ) in Heidelberg have been looking to open up new therapy options for those affected, and have cultivated individual miniature tumours from biopsy samples to test the effectiveness of a variety of drugs within a few weeks.

Predicting the success of cancer treatment - 20/06/2023

Focusing on gut microbiome for CAR T-cell therapy

Cancer immunotherapies use the body's own defences to fight tumour cells. An international consortium of researchers from Germany and the USA led by the DKFZ in Heidelberg has demonstrated that the effectiveness of CAR T-cell therapies greatly depends on the composition of the gut microbiome. The researchers have also developed a model for predicting the long-term response to the treatment.

KIT and Research Center Borstel Present Nanoparticles with a High Antibiotic Concentration for Inhalation – Nanocarriers of Antibiotics Can Reduce Resistances and Enhance Compatibility.

In most cancers, it is not the growth of the primary tumor that determines the prognosis for the patient, but whether it will spread and form metastases. This process is very complex. There are often years between the development of the cancer and the aggressive growth of the metastases. Scientists from the DKFZ, the HI-STEM, the Ruhr University Bochum, Helmholtz Munich and ETH Zurich have studied and identified metastasis growth in breast cancer

Researchers at the Faculty of Medicine at the University of Freiburg have gained significant new insights into metabolic processes in the kidney. The scientists from the Institute of Genetic Epidemiology at the Medical Center - University of Freiburg measured tiny molecules, so-called metabolites, which occur in blood and urine and reflect our metabolism, in samples from more than 5,000 study participants.

Reduced immunosuppression possible in transplantations - 05/06/2023

Modified immune cells produce donor-specific tolerance

Traditionally, transplant recipients have had to take immunosuppressive medication for life to prevent organ rejection. However, there are considerable side effects involved. Using modified immune cells (MICs), TolerogenixX GmbH from Heidelberg has now managed to generate donor-specific tolerance in recipients of living kidney transplants without suppressing the overall immune system.

Detecting drug resistance of tumour cells - 25/05/2023

AI-assisted diagnostics declares war on lung cancer

Lung cancer is one of the most common cancers and has a particularly high mortality rate. A significant challenge in treating this disease lies in the resistance of lung tumours to conventional drug therapies, rendering chemotherapy ineffective. There is hope on the horizon as a team of experts from Baden-Württemberg has joined forces to develop an innovative AI-supported test procedure that paves the way for individualised therapy approaches.

Chronic myeloid leukemia (CML) is a type of blood cancer that arises from malignant changes in blood-forming cells of the bone marrow. It mainly occurs in older individuals and represents about 20 percent of all adult leukemia cases. A research team from the Institute of Molecular Medicine and Cell Research at the University of Freiburg has now demonstrated for the first time that mast cells play a crucial role in the development of CML.